Clinical Trials in Georgia

Showing 8881-8900 of 19,050 trials

DELPHI in Subjects at Risk for Stroke and Dementia

NCT03884647

The DELPhi system is a software device that is used for the noninvasive evaluation of brain plasticity and connectivity. The DELPhi software uses EEG and TMS devices as accessories. Standard electro-physiological acquisition is performed using TMS to evoke regional neuronal potentials measured as EEG data. TMS-EEG data is analyzed with regards to conventional, well established characteristics of neuronal network plasticity and connectivity.

StrokeHypertensionDiabete Mellitus+9 more

QuantalX Neuroscience335 participantsStarted Apr 2020

Walnut Creek, California, United States • Atlanta, Georgia, United States • Norwood, Ohio, United States +1 more locations

COMPLETEDPhase 265 miles

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

NCT03163667

The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the following: * At least 2 lines of therapy, including at least 1 vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) * Radiographic progression of metastatic RCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to cycle 1 day 1

Clear Cell Renal Cell Carcinoma

Calithera Biosciences, Inc69 participantsStarted Sep 2017

Tucson, Arizona, United States • Rogers, Arkansas, United States • Los Angeles, California, United States +35 more locations

DELPHI in Subjects at Risk for Stroke and Dementia

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

Find Trials by Condition in Georgia

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

CAPERE Thrombectomy System Post-Market Clinical Follow Up Study

Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms